ARGX:NSD-argenx NV ADR (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 363.73

Change

+7.07 (+1.98)%

Market Cap

USD 21.62B

Volume

0.56M

Analyst Target

USD 254.56
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-22 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

N/A

USD 122.24B
REGN Regeneron Pharmaceuticals Inc

N/A

USD 115.08B
MRNA Moderna Inc

N/A

USD 51.07B
ALNY Alnylam Pharmaceuticals Inc

N/A

USD 20.96B
BNTX BioNTech SE

N/A

USD 20.40B
BGNE BeiGene Ltd

N/A

USD 17.50B
GMAB Genmab AS

N/A

USD 16.65B
BMRN Biomarin Pharmaceutical Inc

N/A

USD 15.98B
RPRX Royalty Pharma Plc

N/A

USD 15.90B
UTHR United Therapeutics Corporatio..

N/A

USD 13.71B

ETFs Containing ARGX

EWK iShares MSCI Belgium ETF 12.47 % 0.47 %

N/A

USD 0.02B
IBRN iShares Trust - iShares N.. 4.60 % 0.00 %

N/A

USD 3.84M
BBH VanEck Biotech ETF 4.33 % 0.35 %

N/A

USD 0.43B
IBB iShares Biotechnology ETF 1.92 % 0.47 %

N/A

USD 7.43B
XSDR:LSE Xtrackers MSCI Europe Hea.. 1.42 % 0.00 %

N/A

USD 0.16B
DXSE:F Xtrackers Stoxx Europe 60.. 1.42 % 0.00 %

N/A

USD 0.16B
DXSE:XETRA Xtrackers - Stoxx Europe .. 1.42 % 0.00 %

N/A

USD 0.14B
HLTH:LSE SPDR® MSCI Europe Health.. 0.00 % 0.00 %

N/A

USD 0.69B
STW:PA SPDR® MSCI Europe Health.. 0.00 % 0.00 %

N/A

USD 0.70B
EXV4:F iShares STOXX Europe 600 .. 0.00 % 0.00 %

N/A

USD 0.73B
SPYH:F SSgA SPDR ETFs Europe II .. 0.00 % 0.00 %

N/A

USD 0.70B
EXV4:XETRA iShares STOXX Europe 600 .. 0.00 % 0.00 %

N/A

USD 0.70B
SPYH:XETRA SPDR® MSCI Europe Health.. 0.00 % 0.00 %

N/A

USD 0.66B
ESIH:F Ishares VI PLC - Ishares .. 0.00 % 0.00 %

N/A

USD 0.61B
ESIH:XETRA iShares MSCI Europe Healt.. 0.00 % 0.00 %

N/A

USD 0.60B
HEAE:LSE SPDR® MSCI Europe Health.. 0.00 % 0.00 %

N/A

USD 0.70B
STWX:SW SPDR® MSCI Europe Health.. 0.00 % 0.00 %

N/A

USD 0.70B
SXDPEX:SW iShares STOXX Europe 600 .. 0.00 % 0.00 %

N/A

USD 0.44B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -4.22% 51% F 42% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -4.22% 51% F 41% F
Trailing 12 Months  
Capital Gain -9.78% 60% D- 39% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -9.78% 60% D- 38% F
Trailing 5 Years  
Capital Gain 164.76% 89% A- 89% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 164.76% 88% B+ 88% B+
Average Annual (5 Year Horizon)  
Capital Gain 37.33% 83% B 88% B+
Dividend Return 37.33% 83% B 88% B+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 38.43% 71% C- 47% F
Risk Adjusted Return 97.14% 100% F 97% N/A
Market Capitalization 21.62B 99% N/A 96% N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector